Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2025 08:30 ET | Source: Soligenix, Inc.

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands...
December 02, 2025 08:30 ET | Source: BioMedWire

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system,...
November 18, 2025 09:07 ET | Source: Kyowa Kirin

Kyowa Kirin to Present New Research Highlighting Mogamulizumab’s Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting

Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new clinical study data spotlighting the potential...
July 21, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034) | DelveInsight

New York, USA, July 21, 2025 (GLOBE NEWSWIRE) -- Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034) | DelveInsight The...
June 06, 2025 09:37 ET | Source: Soligenix, Inc.

Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and...
September 19, 2024 01:00 ET | Source: Vidac Pharma Holding PLC

U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates

London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class...
March 12, 2024 02:30 ET | Source: Vidac Pharma Holding PLC

Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma

London (UK), March 12, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
August 03, 2021 20:00 ET | Source: DelveInsight Business Research LLP

Promising Treatment for Cutaneous T-cell Lymphoma Enters Clinical Trials

Los Angeles, USA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Promising Treatment for Cutaneous T-cell Lymphoma Enters Clinical Trials Around 25+ key companies are developing Cutaneous T-Cell Lymphoma...
February 03, 2021 01:00 ET | Source: INNATE PHARMA

Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell Lymphomas

MARSEILLE, France, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual...
April 02, 2019 16:04 ET | Source: Kura Oncology, Inc.

Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications

– Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – –...